Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8326 to 8340 of 8908 results

  1. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance

  2. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

    Withdrawn guidance

  3. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Withdrawn guidance

  4. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  5. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    This guidance has been updated and replaced by NICE technology appraisal guidance 824.

    Withdrawn guidance

  6. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

    Withdrawn guidance

  7. Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years) (TA38)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  8. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  9. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

    Withdrawn guidance

  10. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Withdrawn guidance

  11. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Withdrawn guidance

  12. Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) (TA361)

    The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance

  13. Daclatasvir for treating chronic hepatitis C (TA364)

    This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).

    Withdrawn guidance

  14. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Withdrawn guidance

  15. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)

    The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.

    Withdrawn guidance